Effects of protein and calorie restriction on the metabolism and toxicity profile of irinotecan in cancer patients.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
de Man, Femke Mvan Eerden, Ruben A G
van Doorn, Gerdien M
Oomen-de Hoop, Esther
Koolen, Stijn L W
Olieman, Joanne F
de Bruijn, Peter
Veraart, Joris N
van Halteren, Henk K
Sandberg, Yorick
Moelker, Adriaan
IJzermans, Jan N M
Lolkema, Martijn P
van Gelder, Teun
Dollé, Martijn E T
de Bruin, Ron W F
Mathijssen, Ron H J
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Effects of protein and calorie restriction on the metabolism and toxicity profile of irinotecan in cancer patients.Published in
Clin Pharnacol Ther 2021: 109(5):1304-13DOI
10.1002/cpt.2094PMID
33119892ae974a485f413a2113503eed53cd6c53
10.1002/cpt.2094
Scopus Count
Collections
Related articles
- Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
- Authors: Oyaga-Iriarte E, Insausti A, Sayar O, Aldaz A
- Issue date: 2019 May
- Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
- Authors: Brendel K, Bekaii-Saab T, Boland PM, Dayyani F, Dean A, Macarulla T, Maxwell F, Mody K, Pedret-Dunn A, Wainberg ZA, Zhang B
- Issue date: 2021 Dec
- Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
- Authors: Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M
- Issue date: 1995 Feb
- Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
- Authors: Schaaf LJ, Hammond LA, Tipping SJ, Goldberg RM, Goel R, Kuhn JG, Miller LL, Compton LD, Cisar LA, Elfring GL, Gruia G, McGovren JP, Pirotta N, Yin D, Sharma A, Duncan BA, Rothenberg ML
- Issue date: 2006 Jun 15
- Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1 in vitro and in vivo.
- Authors: Qin Y, Wang N, Chen F, Han X, Zhu Y, Rang Y, Zhai X, Lu Y
- Issue date: 2020 May 1